These findings are similar to those published in other studies in which recombinant IL-17A induced proatherogenic changes and increased plaque instability, whilst IL-17A inhibition reduced the development of atherosclerosis [64,67,68,69]. This evidence concerns the gene IL17A and atherosclerosis.